Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.

Gooderham, Melinda J; Forman, Seth B; Bissonnette, Robert; Beebe, Jean S; Zhang, Weidong; Banfield, Chris; Zhu, Linda; Papacharalambous, Jocelyne; Vincent, Michael S; Peeva, Elena

Gooderham, Melinda J; Forman, Seth B; Bissonnette, Robert; Beebe, Jean S; Zhang, Weidong; Banfield, Chris; Zhu, Linda; Papacharalambous, Jocelyne; Vincent, Michael S; Peeva, Elena.

Affiliation

Gooderham MJ; SKiN Centre for Dermatology, Peterborough, Ontario, Canada.
Forman SB; Forward Clinical Trials, Tampa, Florida.
Bissonnette R; Department of Dermatology, Innovaderm Research, Montreal, Quebec, Canada.
Beebe JS; Inflammation and Immunology Research Unit, Pfizer Inc, New York, New York.
Zhang W; Pfizer Innovative Health Statistics, Pfizer Inc, New York, New York.
Banfield C; Early Clinical Development Unit, Pfizer Inc, New York, New York.
Zhu L; Early Clinical Development Unit, Pfizer Inc, New York, New York.
Papacharalambous J; Inflammation and Immunology Research Unit, Pfizer Inc, New York, New York.
Vincent MS; Inflammation and Immunology Research Unit, Pfizer Inc, New York, New York.
Peeva E; Inflammation and Immunology Research Unit, Pfizer Inc, New York, New York.

JAMA Dermatol ; 155(12): 1371-1379, 2019 12 01.

Article de En | MEDLINE | ID: mdl-31577341

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pyrimidines / Sulfonamides / Inhibiteurs de protéines kinases / Eczéma atopique / Janus kinase 1 Type d'étude: Clinical_trials / Diagnostic_studies / Prognostic_studies Limites: Adult / Female / Humans / Male / Middle aged Langue: En Journal: JAMA Dermatol Année: 2019 Type de document: Article Pays d'affiliation: Canada Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google